[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453559":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":62,"collaborators":20,"id":65,"slug":20,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":20,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Azienda Ospedaliero-Universitaria di Modena","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LDLT, partial graft, whole graft recipients","EXPERIMENTAL","Patients that undergo LDLT, partial graft or whole graft transplantation for CRLM in the study period",[13],"Procedure: Living donor liver transplant, Split liver transplant, RAPID, DDLT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Living donor liver transplant, Split liver transplant, RAPID, DDLT","Transplantation of part of the liver from a living donor, or entire cadaveric graft",[9],null,[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Azienda Ospedaliero Universitaria di Modena","RECRUITING","Modena","MO","41124","Italy",{"type":30,"coordinates":31},"Point",[32,33],10.92539,44.64783,{"lat":33,"lon":32},[36,41,44,46,49,50,52,54,56,58,60],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Fabrizio Di Benedetto, MD PhD FACS","CONTACT","+390594225178","fabrizio.dibenedetto@unimore.it",{"name":42,"role":38,"phone":39,"phoneExt":20,"email":43},"Paolo Magistri, MD","paolo.magistri@unimore.it",{"name":37,"role":45,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"name":47,"role":48,"phone":20,"phoneExt":20,"email":20},"Stefano Di Sandro, MD PhD","SUB_INVESTIGATOR",{"name":42,"role":48,"phone":20,"phoneExt":20,"email":20},{"name":51,"role":48,"phone":20,"phoneExt":20,"email":20},"Barbara Catellani, MD",{"name":53,"role":48,"phone":20,"phoneExt":20,"email":20},"Gian Piero Guerrini, MD PhD FACS FEBS",{"name":55,"role":48,"phone":20,"phoneExt":20,"email":20},"Roberto Ballarin, MD PhD",{"name":57,"role":48,"phone":20,"phoneExt":20,"email":20},"Giacomo Assirati, MD",{"name":59,"role":48,"phone":20,"phoneExt":20,"email":20},"Tiziana Olivieri, MD",{"name":61,"role":48,"phone":20,"phoneExt":20,"email":20},"Valentina Serra, MD",{"type":45,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Fabrizio Di Benedetto","Professor","100453559",false,"NCT05186116","LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis","Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: \"Trapianto di Fegato da Donatore Vivente Per Metastasi Epatiche Non Resecabili da Adenocarcinoma Del Colon\"]","LIVERMORE","Inclusion Criteria:\n\n* Age ≥18.\n* Histologically confirmed colon and rectum (intraperitoneal) adenocarcinoma.\n* Pathological classification of primary tumor as pT1-3, without peritoneal tumor deposits, absence of mucinous component \\>50%, confirmed R0 resection, no limitations for RAS mutations, B-RAF wild type.\n* No signs of extra hepatic metastatic disease or local recurrence according to CT scan+MRI+PET\u002FCT scans.\n* Liver metastases not eligible for curative liver resection\n* Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (complete \\[CR\\] or partial response \\[PR\\] or standard disease \\[SD\\]) during second- line treatment for at least 4 months.\n* Carcinoembryonic Antigen (CEA) values stable or decreasing during the enrollment prior to liver transplant.\n* Performance status, ECOG (Eastern Cooperative Oncology Group) 0-2.\n* Signed informed consent and expected cooperation of the patients for the treatment and follow-up, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Hereditary CRC syndromes including FAP (Familial adenomatous polyposis) and Lynch syndrome.\n* Prior extra hepatic metastatic disease or primary tumor local relapse.\n* Palliative resection of primary CRC tumor.\n* Disease progression\n* Other malignancies in the previous 5 years (with exception of in situ cervical carcinoma and basal cell carcinoma; superficial bladder tumors are allowed if curatively treated).\n* Active intra-venous or alcohol abusers (patients may be eligible if abstention \\> 6 months is demonstrated)\n* Active HIV infection\n* Psychiatric disorders and patient low compliance\n* Any reason why, in the judgment of the investigators, the patient should not participate (to be formally declared)","ALL","18 Years","77 Years",{"count":76,"type":77},25,"ESTIMATED","INTERVENTIONAL",[80],"NA","This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM.\n\nSecondary outcomes are graft survival and donor outcomes in terms of safety and quality of life.\n\nDonor selection is performed according to the currently used Institutional and National standards and protocols.",[83,84],"Colon Adenocarcinoma","Liver Metastasis Colon Cancer",[86,87,88,89],"LDLT","living donor","CRLM","transplant oncology","2025-09-20",{"date":92,"type":93},"2025-09-25","ACTUAL",{"date":95,"type":93},"2022-01-01",{"date":97,"type":77},"2032-01-01",{"name":5,"class":6},1]